Jetzt anmelden und diskutieren
Registrieren
Login
Key Dates and Disclosure Events Shareholders Need to Know
NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Nektar Therapeutics (NASDAQ: NKTR) to contact the firm. Those who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be entitled to recover damages. Find out if you are eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) Suewallst.
Nektar shares fell $4.14 per share, or 7.77%, closing at $49.16 on December 16, 2025 after trial results revealed four ineligible patients had been enrolled in the pivotal REZOLVE-AA study. The window to apply for lead plaintiff closes on May 5, 2026.
Chronology of Material Events
The timeline of public statements and disclosures in this securities action spans ten months. At each stage, the lawsuit contends, management reinforced a narrative of rigorous enrollment standards while concealing that those standards had been violated.
The Pattern That Emerged
The securities action alleges that across each of these dates, the same enrollment criteria were publicly cited as evidence of trial rigor while the Company knew or recklessly disregarded that violations of those very criteria had occurred. Two patients allegedly had unstable alopecia areata diagnosed less than six months before randomization. Two others allegedly began treatment before completing the mandatory eight-week washout period for prior medications.
Submit your claim before the deadline or call (212) 363-7500.
"Timely disclosure of material developments is fundamental to fair and efficient markets. The complaint raises questions about why known protocol deviations were not disclosed to investors who relied on repeated assurances of enrollment integrity across multiple quarters." -- Joseph E. Levi, Esq.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Those wishing to serve as lead plaintiff must act by May 5, 2026.
CONTACT:
SueWallSt
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/nktr-investor-alert-nektar-therapeutics-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-allegedly-hiding-enrollment-protocol-failures-suewallst-302725896.html
SOURCE SueWallSt.com
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
